Specifically, HDAC inhibitors have been approved in the treatment of cutaneous T-cell lymphoma, where HDAC inhibitors drive the terminal differentiation of cancer cells [30]. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.